Li, Lily
Eli Lilly (United States)
2 papers on CoChatORCID 0000-0002-9794-8468
Most cited papers
- Verified
Abstract CT232: clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Cancer Research
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 44
- Verified
Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma
Morschhauser, F., Bouabdallah, K., Stilgenbauer, S., Thieblemont, C., Wolf, M., de Guibert, S., Zettl, F., Hahka-Kemppinen, M., Xiaohui Wang, D., Brueck, P., et al. (2014) · Blood
Lymphoma Diagnosis and TreatmentAdvanced Breast Cancer Therapies
Cited by 20
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free